{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:53:00Z","timestamp":1792705980624,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000940","name":"Arthritis Australia","doi-asserted-by":"crossref","award":["GA76063"],"award-info":[{"award-number":["GA76063"]}],"id":[{"id":"10.13039\/501100000940","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Systematic r\neview to evaluate the quality of the clinical practice guidelines (CPG) for rheumatoid arthritis (RA) management and to provide a synthesis of high-quality CPG recommendations, highlighting areas of consistency, and inconsistency. Electronic searches of five databases and four online guideline repositories were performed. RA management CPGs were eligible for inclusion if they were written in English and published between January 2015 and February 2022; focused on adults\u2009\u2265\u200918\u00a0years of age; met the criteria of a CPG as defined by the Institute of Medicine; and were rated as high quality on the Appraisal of Guidelines for Research and Evaluation II instrument. RA CPGs were excluded if they required additional payment to access; only addressed recommendations for the system\/organization of care and did not include interventional management recommendations; and\/or included other arthritic conditions. Of 27 CPGs identified, 13 CPGs met eligibility criteria and were included. Non-pharmacological care should include patient education, patient-centered care, shared decision-making, exercise, orthoses, and a multi-disciplinary approach to care. Pharmacological care should include conventional synthetic disease modifying anti-rheumatic drugs (DMARDs), with methotrexate as the first-line choice. If monotherapy conventional synthetic DMARDs fail to achieve a treatment target, this should be followed by combination therapy conventional synthetic DMARDs (leflunomide, sulfasalazine, hydroxychloroquine), biologic DMARDS and targeted synthetic DMARDS. Management should also include monitoring, pre-treatment investigations and vaccinations, and screening for tuberculosis and hepatitis. Surgical care should be recommended if non-surgical care fails. This synthesis offers clear guidance of evidence-based RA care to healthcare providers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      The protocol for this review was registered with Open Science Framework (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.17605\/OSF.IO\/UB3Y7\">https:\/\/doi.org\/10.17605\/OSF.IO\/UB3Y7<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-023-06654-0","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T21:01:54Z","timestamp":1686258114000},"page":"2267-2278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-4540","authenticated-orcid":false,"given":"Brooke","family":"Conley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bunzli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Bullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Persaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilini","family":"Gunatillake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Barnabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"issue":"5","key":"6654_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00296-020-04731-0","volume":"41","author":"K Almutairi","year":"2021","unstructured":"Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C (2021) The global prevalence of rheumatoid arthritis: a meta-analysis based on a systematic review. Rheumatol Int 41(5):863\u2013877. https:\/\/doi.org\/10.1007\/s00296-020-04731-0","journal-title":"Rheumatol Int"},{"key":"6654_CR2","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.3390\/cells10112857","volume":"11","author":"AF Radu","year":"2021","unstructured":"Radu AF, Bungau SG (2021) Management of rheumatoid arthritis: an overview. Cells. 11:2857. https:\/\/doi.org\/10.3390\/cells10112857","journal-title":"Cells."},{"issue":"10","key":"6654_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1586\/1744666X.2015.1067606","volume":"11","author":"GS Metsios","year":"2015","unstructured":"Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD (2015) The role of exercise in the management of rheumatoid arthritis. Expert Rev Clin Immunol 11(10):1121\u20131130. https:\/\/doi.org\/10.1586\/1744666X.2015.1067606","journal-title":"Expert Rev Clin Immunol"},{"issue":"S1","key":"6654_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4081\/reumatismo.2019.1202","volume":"71","author":"S Parisi","year":"2019","unstructured":"Parisi S, Bortoluzzi A, Sebastiani GD, Conti F, Caporali R, Ughi N, Prevete I, Ariani A, Manara M, Carrara G, Scir\u00e8 CA (2019) The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis. Reumatismo 71(S1):22\u201349. https:\/\/doi.org\/10.4081\/reumatismo.2019.1202","journal-title":"Reumatismo"},{"issue":"6","key":"6654_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1136\/annrheumdis-2019-216243","volume":"79","author":"PH Hsieh","year":"2020","unstructured":"Hsieh PH, Wu O, Geue C, McIntosh E, McInnes IB, Siebert S (2020) Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Ann Rheum Dis 79(6):771\u2013777. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216243","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6654_CR6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/acr.24042","volume":"71","author":"BR England","year":"2019","unstructured":"England BR, Tiong BK, Bergman MJ, Curtis JR, Kazi S, Mikuls TR, O\u2019Dell JR, Ranganath VK, Limanni A, Suter LG, Michaud K (2019) 2019 update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res 71(12):1540\u20131555. https:\/\/doi.org\/10.1002\/acr.24042","journal-title":"Arthritis Care Res"},{"issue":"5","key":"6654_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, Saag KG, O\u2019dell JR, Kazi S. (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res 64(5):640\u2013647. https:\/\/doi.org\/10.1002\/acr.21649","journal-title":"Arthritis Care Res"},{"issue":"3","key":"6654_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.5606\/ArchRheumatol.2018.6911","volume":"33","author":"\u015e Ataman","year":"2018","unstructured":"Ataman \u015e, Sunar I, Yilmaz G, Bodur H, Kemal NA, Ayhan FF, Akg\u00fcl \u00d6, Akinci A, Altay Z, Birtane M, Bu\u011fdayci DS (2018) Turkish League Against Rheumatism (TLAR) recommendations for the pharmacological management of rheumatoid arthritis: 2018 update under guidance of current recommendations. Arch Rheumatol 33(3):251. https:\/\/doi.org\/10.5606\/ArchRheumatol.2018.6911","journal-title":"Arch Rheumatol"},{"issue":"1","key":"6654_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13047-016-0167-0","volume":"9","author":"K Hennessy","year":"2016","unstructured":"Hennessy K, Woodburn J, Steultjens M (2016) Clinical practice guidelines for the foot and ankle in rheumatoid arthritis: a critical appraisal. J Foot Ankle Res 9(1):1\u20133. https:\/\/doi.org\/10.1186\/s13047-016-0167-0","journal-title":"J Foot Ankle Res"},{"key":"6654_CR10","unstructured":"Robin G, Michelle M, Dianne MW. Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Clinical Practice Guidelines We Can Trust"},{"issue":"3","key":"6654_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.mayocp.2017.01.001","volume":"92","author":"MH Murad","year":"2017","unstructured":"Murad MH (2017) Clinical practice guidelines: a primer on development and dissemination. In Mayo Clin Proceed 92(3):423\u2013433. https:\/\/doi.org\/10.1016\/j.mayocp.2017.01.001","journal-title":"In Mayo Clin Proceed"},{"issue":"10","key":"6654_CR12","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1093\/rheumatology\/ker195","volume":"50","author":"EJ Hurkmans","year":"2011","unstructured":"Hurkmans EJ, Jones A, Li LC, Vliet Vlieland TP (2011) Quality appraisal of clinical practice guidelines on the use of physiotherapy in rheumatoid arthritis: a systematic review. Rheumatology 50(10):1879\u20131888. https:\/\/doi.org\/10.1093\/rheumatology\/ker195","journal-title":"Rheumatology"},{"issue":"2","key":"6654_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/bjsports-2018-099878","volume":"54","author":"I Lin","year":"2020","unstructured":"Lin I, Wiles L, Waller R, Goucke R, Nagree Y, Gibberd M, Straker L, Maher CG, O\u2019Sullivan PP (2020) What does best practice care for musculoskeletal pain look like? Eleven consistent recommendations from high-quality clinical practice guidelines: systematic review. British J Sports Med 54(2):79\u201386. https:\/\/doi.org\/10.1136\/bjsports-2018-099878","journal-title":"British J Sports Med"},{"issue":"7182","key":"6654_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/bmj.318.7182.527","volume":"318","author":"SH Woolf","year":"1999","unstructured":"Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J (1999) Potential benefits, limitations, and harms of clinical guidelines. BMJ 318(7182):527\u2013530. https:\/\/doi.org\/10.1136\/bmj.318.7182.527","journal-title":"BMJ"},{"key":"6654_CR15","doi-asserted-by":"publisher","unstructured":"Ng JY, Azizudin AM (2021) Quantity and quality of rheumatoid arthritis and osteoarthritis clinical practice guidelines: systematic review and assessment using AGREE II current treatment options in rheumatology. (7)134\u201349. https:\/\/doi.org\/10.1007\/s40674-021-00172-3","DOI":"10.1007\/s40674-021-00172-3"},{"issue":"1","key":"6654_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41927-019-0090-7","volume":"3","author":"A Mian","year":"2019","unstructured":"Mian A, Ibrahim F, Scott DL (2019) A systematic review of guidelines for managing rheumatoid arthritis. BMC Rheumatol 3(1):1\u20133. https:\/\/doi.org\/10.1186\/s41927-019-0090-7","journal-title":"BMC Rheumatol"},{"issue":"2","key":"6654_CR17","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.eujim.2014.01.009","volume":"6","author":"Y Yuwen","year":"2014","unstructured":"Yuwen Y, Han X, Shi N, Wang L, Liao X, Zhong I, Bian Z, Lyu A (2014) Appraisal of clinical practice guidelines for the management of rheumatoid arthritis in traditional Chinese medicine using the AGREE II instrument: a systematic review. Eur J Integ Med 6(2):176\u2013185","journal-title":"Eur J Integ Med"},{"issue":"4","key":"6654_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group* T (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 151(4):264\u20139. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135","journal-title":"Ann Int Med"},{"issue":"88","key":"6654_CR19","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"1","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 1(88):105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906","journal-title":"Int J Surg"},{"key":"6654_CR20","doi-asserted-by":"crossref","unstructured":"Conley B, Bunzli S, Bullen J, O\u2019Brien P, Persaud J, Gunatillake T, Dowsey M. M, Choong P, Lin I (2023) What are the core recommendations for osteoarthritis care? A systematic review of clinical practice guidelines. Arthritis care & research","DOI":"10.1002\/acr.25101"},{"key":"6654_CR21","unstructured":"Brouwers (2017). The AGREE II Instrument [Electronic version]"},{"issue":"10","key":"6654_CR22","doi-asserted-by":"publisher","first-page":"E472","DOI":"10.1503\/cmaj.091716","volume":"182","author":"MC Brouwers","year":"2010","unstructured":"Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Hanna SE, Makarski J (2010) Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ 182(10):E472\u2013E478. https:\/\/doi.org\/10.1503\/cmaj.091716","journal-title":"CMAJ"},{"issue":"10","key":"6654_CR23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1503\/cmaj.091714","volume":"182","author":"MC Brouwers","year":"2010","unstructured":"Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Hanna SE, Makarski J (2010) Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ 182(10):1045\u20131052. https:\/\/doi.org\/10.1503\/cmaj.091714","journal-title":"CMAJ"},{"key":"6654_CR24","doi-asserted-by":"crossref","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. biometrics. 33(1)159\u201374","DOI":"10.2307\/2529310"},{"key":"6654_CR25","unstructured":"Fleiss, Joseph L. Statistical methods for rates and proportions. 2. Hoboken, New Jersey: Wiley; 1981"},{"issue":"9","key":"6654_CR26","doi-asserted-by":"publisher","first-page":"e0137180","DOI":"10.1371\/journal.pone.0137180","volume":"10","author":"CA Smith","year":"2015","unstructured":"Smith CA, Toupin-April K, Jutai JW, Duffy CM, Rahman P, Cavallo S, Brosseau L (2015) A systematic critical appraisal of clinical practice guidelines in juvenile idiopathic arthritis using the appraisal of guidelines for research and evaluation II (AGREE II) instrument. PloS one 10(9):e0137180. https:\/\/doi.org\/10.1371\/journal.pone.0137180","journal-title":"PloS one"},{"key":"6654_CR27","volume-title":"clinical practice guidelines for the management of patients with rheumatoid arthritis","author":"GUIPCAR working group","year":"2019","unstructured":"GUIPCAR working group (2019) clinical practice guidelines for the management of patients with rheumatoid arthritis. Spanish Society of Rheumatology (SER), Madrid"},{"key":"6654_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s42358-018-0005-0","volume":"29","author":"LM Mota","year":"2019","unstructured":"Mota LM, Kakehasi AM, Gomides AP, Duarte AL, Cruz BA, Brenol CV, Albuquerque CP, Pinheiro GD, Pereira IA, Bertolo MB, Souza MP (2019) 2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis. Adv Rheumatol 29:58. https:\/\/doi.org\/10.1186\/s42358-018-0005-0","journal-title":"Adv Rheumatol"},{"key":"6654_CR29","unstructured":"Malaysia Health Technology Assessment Section (MaHTAS) (2019) Management of rheumatoid arthritis clinical practice guidelines. Retrieved from https:\/\/www.moh.gov.my\/moh\/resources\/Penerbitan\/CPG\/2)_CPG_Management_of_Rheumatoid_Arthritis.pdf"},{"issue":"7","key":"6654_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/1756-185X.12754","volume":"18","author":"CS Lau","year":"2015","unstructured":"Lau CS, Chia F, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ (2015) APLAR rheumatoid arthritis treatment recommendations. Int J Rheum Dis 18(7):685\u2013713. https:\/\/doi.org\/10.1111\/1756-185X.12754","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"6654_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13047-018-0276-z","volume":"11","author":"M Tenten-Diepenmaat","year":"2018","unstructured":"Tenten-Diepenmaat M, van der Leeden M, Vliet Vlieland TP, Dekker J (2018) Multidisciplinary recommendations for diagnosis and treatment of foot problems in people with rheumatoid arthritis. J foot Ankle Res 11(1):1\u20133. https:\/\/doi.org\/10.1186\/s13047-018-0276-z","journal-title":"J foot Ankle Res"},{"issue":"1","key":"6654_CR32","first-page":"40","volume":"46","author":"EJ Santos","year":"2021","unstructured":"Santos EJ, Duarte C, Ferreira RJ, Pinto AM, Moreira A, Vaz C, Branco CA, Mateus E, Canh\u00e3o H, Campos I, Barbosa I (2021) Portuguese multidisciplinary recommendations for non-pharmacological and non-surgical interventions in patients with rheumatoid arthritis. Acta Reumatol Port 46(1):40\u201354","journal-title":"Acta Reumatol Port"},{"issue":"8","key":"6654_CR33","doi-asserted-by":"publisher","first-page":"pzab127","DOI":"10.1093\/ptj\/pzab127","volume":"101","author":"WF Peter","year":"2021","unstructured":"Peter WF, Swart NM, Meerhoff GA, Vliet Vlieland TP (2021) Clinical practice guideline for physical therapist management of people with rheumatoid arthritis. Phys Ther 101(8):pzab127. https:\/\/doi.org\/10.1093\/ptj\/pzab127","journal-title":"Phys Ther"},{"issue":"1","key":"6654_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, Caporali R, Edwards CJ, Hyrich KL, Pope JE, de Souza S, Stamm TA, Takeuchi T, Verschueren P, Winthrop KL, Balsa A, Bathon JM, Buch MH, Burmester GR, Buttgereit F, Cardiel MH, Chatzidionysiou K, Codreanu C, Cutolo M, den Broeder AA, El Aoufy K, Finckh A, Fonseca JE, Gottenberg JE, Haavardsholm EA, Iagnocco A, Lauper K, Li Z, McInnes IB, Mysler EF, Nash P, Poor G, Ristic GG, Rivellese F, Rubbert-Roth A, Schulze-Koops H, Stoilov N, Strangfeld A, van der Helm-van MA, van Duuren E, Vliet Vlieland TPM, Westhovens R, van der Heijde D (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"6654_CR35","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, St. Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J (2021) American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 73(7):1108\u201323. https:\/\/doi.org\/10.1002\/art.41752","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"6654_CR36","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3899\/jrheum.220209","volume":"49","author":"GS Hazlewood","year":"2022","unstructured":"Hazlewood GS, Pardo JP, Barnabe C, Schieir O, Barber CE, Proulx L, Richards DP, Tugwell P, Bansback N, Akhavan P, Bombardier C (2022) Canadian Rheumatology Association living guidelines for the pharmacological management of rheumatoid arthritis with disease-modifying antirheumatic drugs. J Rheumatol 49(10):1092\u20131099. https:\/\/doi.org\/10.3899\/jrheum.220209","journal-title":"J Rheumatol"},{"key":"6654_CR37","volume-title":"diagnosis and management","author":"Rheumatoid arthritis in adults","year":"2018","unstructured":"Rheumatoid arthritis in adults (2018) diagnosis and management. National Institute for Health and Care Excellence (NICE), London"},{"issue":"9","key":"6654_CR38","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1111\/1756-185X.12905","volume":"20","author":"W Katchamart","year":"2017","unstructured":"Katchamart W, Narongroeknawin P, Chevaisrakul P, Dechanuwong P, Mahakkanukrauh A, Kasitanon N, Pakchotanon R, Sumethkul K, Ueareewongsa P, Ukritchon S, Bhurihirun T (2017) Evidence-based recommendations for the diagnosis and management of rheumatoid arthritis for non-rheumatologists: integrating systematic literature research and expert opinion of the Thai Rheumatism Association. Int J Rheum Dis 20(9):1142\u20131165. https:\/\/doi.org\/10.1111\/1756-185X.12905","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"6654_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","volume":"22","author":"CS Lau","year":"2019","unstructured":"Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22(3):357\u2013375. https:\/\/doi.org\/10.1111\/1756-185X.13513","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"6654_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jbspin.2018.10.002","volume":"86","author":"C Daien","year":"2019","unstructured":"Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, Fautrel B, Mariette X, Nayral N, Richez C, Saraux A (2019) Update of French society for rheumatology recommendations for managing rheumatoid arthritis. Joint Bone Spine 86(2):135\u2013150. https:\/\/doi.org\/10.1016\/j.jbspin.2018.10.002","journal-title":"Joint Bone Spine"},{"key":"6654_CR41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00296-019-04372-y","volume":"39","author":"H Alhajeri","year":"2019","unstructured":"Alhajeri H, Abutiban F, Al-Adsani W, Al-Awadhi A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkandari W, Dehrab A, MuhannaGhanem AA (2019) Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. Rheumatol Int 39:1483\u20131497. https:\/\/doi.org\/10.1007\/s00296-019-04372-y","journal-title":"Rheumatol Int"},{"issue":"4","key":"6654_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.reuma.2019.04.002","volume":"17","author":"MH Cardiel","year":"2021","unstructured":"Cardiel MH, Carrillo S, P\u00e9rez M, Andrade L, Tena CP, Silveira LH, Lim\u00f3n L, Cerpa S, Ure\u00f1a SG, Dur\u00e1n S, Palazuelos FI (2021) Update of the Mexican College of Rheumatology guidelines for the pharmacological treatment of rheumatoid arthritis, 2018. Reumatolog\u00eda Cl\u00ednica (English Edition) 17(4):215\u2013228. https:\/\/doi.org\/10.1016\/j.reuma.2019.04.002","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)"},{"issue":"3","key":"6654_CR43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.reuma.2016.10.002","volume":"13","author":"R Garc\u00eda-Vicu\u00f1a","year":"2017","unstructured":"Garc\u00eda-Vicu\u00f1a R, Mart\u00edn-Mart\u00ednez MA, Gonzalez-Crespo MR, Tornero-Molina J, Fern\u00e1ndez-Nebro A, Blanco-Garc\u00eda FJ, Blanco-Alonso R, Marsal-Barril S, enrepresentaci\u00f3n del Comit\u00e9Cient\u00edfico del trabajo de Recomendaciones de la Sociedad Espa\u00f1ola de Reumatolog\u00eda para el manejocl\u00ednico del paciente con artritisreumatoide que no puedeutilizarmetotrexato (2017) Recommendations by the Spanish Society of Rheumatology for the management of patients diagnosed with rheumatoid arthritis who cannot be treated with methotrexate. Reumatol Clin. 13(3):127\u2013138. https:\/\/doi.org\/10.1016\/j.reuma.2016.10.002","journal-title":"Reumatol Clin."},{"issue":"5","key":"6654_CR44","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.reuma.2015.05.001","volume":"11","author":"R Sanmart\u00ed","year":"2015","unstructured":"Sanmart\u00ed R, Garc\u00eda-Rodr\u00edguez S, \u00c1lvaro-Gracia JM, Andreu JL, Balsa A, C\u00e1liz R, Fern\u00e1ndez-Nebro A, Ferraz-Amaro I, G\u00f3mez-Reino JJ, Gonz\u00e1lez-\u00c1lvaro I, Mart\u00edn-Mola E (2015) 2014 update of the consensus statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatolog\u00eda Cl\u00ednica (English Edition). 11(5):279\u201394. https:\/\/doi.org\/10.1016\/j.reuma.2015.05.001","journal-title":"Reumatolog\u00eda Cl\u00ednica (English Edition)."},{"key":"6654_CR45","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.rbr.2015.08.004","volume":"55","author":"LM Mota","year":"2015","unstructured":"Mota LM, Cruz BA, Albuquerque CP, Gon\u00e7alves DP, Laurindo IM, Pereira IA, Carvalho JF, Pinheiro GD, Bertolo MB, Pinto MR, Louzada-Junior P (2015) Update on the 2012 Brazilian Society of Rheumatology Guidelines for the treatment of rheumatoid arthritis: position on the use of tofacitinib. Rev Bras Reumatol 55:512\u2013521. https:\/\/doi.org\/10.1016\/j.rbr.2015.08.004","journal-title":"Rev Bras Reumatol"},{"issue":"9","key":"6654_CR46","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/1756-185X.13130","volume":"20","author":"W Louthrenoo","year":"2017","unstructured":"Louthrenoo W, Kasitanon N, Katchamart W, Aiewruengsurat D, Chevaisrakul P, Chiowchanwisawakit P, Dechanuwong P, Hanvivadhanakul P, Mahakkanukrauh A, Manavathongchai S, Muangchan C (2017) 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Int J Rheum Dis 20(9):1166\u20131184. https:\/\/doi.org\/10.1111\/1756-185X.13130","journal-title":"Int J Rheum Dis"},{"key":"6654_CR47","doi-asserted-by":"publisher","first-page":"608703","DOI":"10.3389\/fphar.2020.608703","volume":"11","author":"N Lin","year":"2021","unstructured":"Lin N, Zhang YQ, Jiang Q, Liu W, Liu J, Huang QC, Wu KY, Tu SH, Zhou ZS, Chen WH, Li XX (2021) Clinical practice guideline for tripterygium glycosides\/tripterygium wilfordii tablets in the treatment of rheumatoid arthritis. Front Pharmacol 11:608703. https:\/\/doi.org\/10.3389\/fphar.2020.608703","journal-title":"Front Pharmacol"},{"issue":"1","key":"6654_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14397595.2018.1472358","volume":"29","author":"H Kameda","year":"2019","unstructured":"Kameda H, Fujii T, Nakajima A, Koike R, Sagawa A, Kanbe K, Tomita T, Harigai M, Suzuki Y (2019) Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Modern Rheumatol 29(1):31\u201340. https:\/\/doi.org\/10.1080\/14397595.2018.1472358","journal-title":"Modern Rheumatol"},{"issue":"1","key":"6654_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68(1):1\u201326. https:\/\/doi.org\/10.1002\/art.39480","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"6654_CR50","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, Van Vollenhoven R, Aletaha D (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960\u2013977. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6654_CR51","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, Van Vollenhoven RF, De Wit M, Aletaha D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"6654_CR52","doi-asserted-by":"publisher","unstructured":"Tetreault L, Nater A, Garwood P, Badhiwala JH, Wilson JR, Fehlings MG (2019) Development and implementation of clinical practice guidelines: an update and synthesis of the literature with a focus in application to spinal conditions. Glob Spine J (1_suppl):53S-64S. https:\/\/doi.org\/10.1177\/2192568219831689","DOI":"10.1177\/2192568219831689"},{"issue":"1","key":"6654_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1017\/S1463423611000405","volume":"13","author":"A McKillop","year":"2012","unstructured":"McKillop A, Crisp J, Walsh K (2012) Practice guidelines need to address the \u2018how\u2019and the \u2018what\u2019of implementation. Primary Health Care Res Develop 13(1):48\u201359. https:\/\/doi.org\/10.1017\/S1463423611000405","journal-title":"Primary Health Care Res Develop"},{"issue":"1","key":"6654_CR54","doi-asserted-by":"publisher","first-page":"e000195","DOI":"10.1136\/rmdopen-2015-000195","volume":"2","author":"N Lesuis","year":"2016","unstructured":"Lesuis N, den Broeder AA, Hulscher ME, van Vollenhoven RF (2016) Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists. RMD open. 2(1):e000195. https:\/\/doi.org\/10.1136\/rmdopen-2015-000195","journal-title":"RMD open."},{"issue":"7","key":"6654_CR55","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1515\/cclm-2015-0871","volume":"54","author":"JH Barth","year":"2016","unstructured":"Barth JH, Misra S, Aakre KM, Langlois MR, Watine J, Twomey PJ, Oosterhuis WP (2016) Why are clinical practice guidelines not followed? Clin Chem Lab Med (CCLM) 54(7):1133\u20131139. https:\/\/doi.org\/10.1515\/cclm-2015-0871","journal-title":"Clin Chem Lab Med (CCLM)"},{"issue":"5","key":"6654_CR56","doi-asserted-by":"publisher","first-page":"e95369","DOI":"10.1371\/journal.pone.0095369","volume":"9","author":"L Brosseau","year":"2014","unstructured":"Brosseau L, Rahman P, Poitras S, Toupin-April K, Paterson G, Smith C, King J, Casimiro L, De Angelis G, Loew L, Cavallo S (2014) A systematic critical appraisal of non-pharmacological management of rheumatoid arthritis with appraisal of guidelines for research and evaluation II. PLoS One 9(5):e95369. https:\/\/doi.org\/10.1371\/journal.pone.0095369","journal-title":"PLoS One"},{"issue":"11","key":"6654_CR57","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jclinepi.2014.07.005","volume":"67","author":"GS Hazlewood","year":"2014","unstructured":"Hazlewood GS, Akhavan P, Schieir O, Marshall D, Tomlinson G, Bykerk V, Bombardier C (2014) Adding a \u201cGRADE\u201d to the quality appraisal of rheumatoid arthritis guidelines identifies limitations beyond AGREE-II. J Clin Epidemiol 67(11):1274\u201385. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.07.005","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"6654_CR58","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/acr.23865","volume":"72","author":"MA Lopez-Olivo","year":"2020","unstructured":"Lopez-Olivo MA, Colmegna I, KarpesMatusevich AR, Qi SR, Zamora NV, Sharma R, Pratt G, Suarez-Almazor ME (2020) Systematic review of recommendations on the use of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and cancer. Arthritis Care Res 72(3):309\u2013318. https:\/\/doi.org\/10.1002\/acr.23865","journal-title":"Arthritis Care Res"},{"key":"6654_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12961-020-00588-8","volume":"18","author":"VC Correa","year":"2020","unstructured":"Correa VC, Lugo-Agudelo LH, Aguirre-Acevedo DC, Contreras JA, Borrero AM, Pati\u00f1o-Lugo DF, Valencia DA (2020) Individual, health system, and contextual barriers and facilitators for the implementation of clinical practice guidelines: a systematic metareview. Health Res Policy Syst 18:1\u20131. https:\/\/doi.org\/10.1186\/s12961-020-00588-8","journal-title":"Health Res Policy Syst"},{"issue":"1","key":"6654_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"6","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6(1):15. https:\/\/doi.org\/10.1038\/s41413-018-0016-9","journal-title":"Bone Res"},{"issue":"7","key":"6654_CR61","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1002\/jcp.27860","volume":"234","author":"M Abbasi","year":"2019","unstructured":"Abbasi M, Mousavi MJ, Jamalzehi S, Alimohammadi R, Bezvan MH, Mohammadi H, Aslani S (2019) Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol 234(7):10018\u201310031. https:\/\/doi.org\/10.1002\/jcp.27860","journal-title":"J Cell Physiol"},{"issue":"2","key":"6654_CR62","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/rheumatology\/keab330","volume":"61","author":"GS Hazlewood","year":"2022","unstructured":"Hazlewood GS, Loyola-Sanchez A, Bykerk V, Hull PM, Marshall D, Pham T, Barber CE, Barnabe C, Sirois A, Pope J, Schieir O (2022) Patient and rheumatologist perspectives on tapering DMARDs in rheumatoid arthritis: a qualitative study. Rheumatology 61(2):606\u2013616. https:\/\/doi.org\/10.1093\/rheumatology\/keab330","journal-title":"Rheumatology"},{"key":"6654_CR63","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1007\/s10067-020-05358-z","volume":"39","author":"R Roongta","year":"2020","unstructured":"Roongta R, Ghosh A (2020) Managing rheumatoid arthritis during COVID-19. Clin Rheumatol 39:3237\u20133244. https:\/\/doi.org\/10.1007\/s10067-020-05358-z","journal-title":"Clin Rheumatol"},{"issue":"6","key":"6654_CR64","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.jbspin.2016.07.007","volume":"83","author":"E Minichiello","year":"2016","unstructured":"Minichiello E, Semerano L, Boissier MC (2016) Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: a systematic literature review. Joint Bone Spine 83(6):625\u2013630. https:\/\/doi.org\/10.1016\/j.jbspin.2016.07.007","journal-title":"Joint Bone Spine"},{"issue":"5","key":"6654_CR65","first-page":"862","volume":"37","author":"A Doria","year":"2019","unstructured":"Doria A, Zavaglia D (2019) Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. Clin Exp Rheumatol 37(5):862\u201371","journal-title":"Clin Exp Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06654-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06654-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T07:10:15Z","timestamp":1691565015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06654-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":65,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6654"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06654-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"15 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Professor Cheryl Barnabe\u2014Past 2\u00a0years\u2014speaking fees from Fresenius Kabi, Janssen, Pfizer; advisory board fees from Celltrion Healthcare, Sanofi Genzyme. There are no other competing interests for the remaining authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}